None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Presence of two or more symptoms of allergic rhinitis(nasal congestion, rhinorrhea, nasal itching and sneezing) and Positive reaction to an allergen in multiple allergen simultaneous test
Exclusion criteria
Exclusion criteria: 1) Patients who take any medication as follows or who can’t stop taking medication which is unsuitable for this clinical trail.(But they can be enrolled in this trial after the minimum Wash-out period as suggested, before Visit2.) ? anti-histamine/H1 blockers within the last 7days ? corticosteroids(intranasal) within the last 14days ? corticosteroids(systemic) within the last 30days ? anti-cholinergic drug within the last 7days ? anti-leukotriene drug within the last 4weeks ? decongestants within the last 3days ? tricyclic antidepressants, phenothiazines within the last 14days ? non-steroidal analgesics within the last 14days ? Others (inappropriate medications) 2) Korean Medicine treatment(herbal medicine, acupuncture, moxibustion, cupping, etc) to treat allergic rhinitis within the last 14days 3) Laser therapy to treat allergic rhinitis within the last 14days 4) Patients who have had treatments due to acute upper respiratory infections or sinusitis, within the last 4weeks 5) Non-allergic rhinitis such as vasomotor, infectious, drug-induced rhinitis, or other severe nasal illness 6) Anatomical obstruction or deformities of the nasal cavity or nasal surgery within the past 6 months 7) Malignant neoplasm, anemia, active pulmonary tuberculosis, infection or other severe systemic disease 8) Past history of active respiratory disease like asthma 9) Immunotherapy or systemic corticosteroids therapy within the last 5 years 10) hypersensitivity reaction to phototherapy or taking related drugs 11) scar on the irradiation(or acupuncture) spot 12) Pregnancy, planning a pregnancy or breast-feeding 13) Participation in other clinical trials within the last 1 month 14) Difficulties in enrolling this trial or receiving treatment 15) Ineligibility for participation as judged by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TNSS (total nasal symptom score) | — |
Secondary
| Measure | Time frame |
|---|---|
| RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire);Serum ImmunoglobulinE, Eosinophil count;Nasal endoscopy;Adverse event | — |
Countries
Korea, Republic of
Contacts
Woosuk University